Gluskin Sheff & Assoc Inc. increased its stake in shares of Allergan PLC. (NYSE:AGN) by 59.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,681 shares of the company’s stock after acquiring an additional 38,683 shares during the quarter. Allergan PLC. makes up about 2.3% of Gluskin Sheff & Assoc Inc.’s portfolio, making the stock its 18th largest position. Gluskin Sheff & Assoc Inc.’s holdings in Allergan PLC. were worth $25,204,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Pathstone Family Office LLC increased its holdings in shares of Allergan PLC. by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after acquiring an additional 366 shares in the last quarter. Howard Hughes Medical Institute acquired a new position in shares of Allergan PLC. during the second quarter worth approximately $103,000. Jacobi Capital Management LLC raised its position in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the period. JNBA Financial Advisors raised its position in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after purchasing an additional 12 shares during the period. Finally, Pacific Center for Financial Services raised its position in shares of Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after purchasing an additional 475 shares during the period. Institutional investors and hedge funds own 82.03% of the company’s stock.

AGN has been the topic of a number of recent research reports. Wells Fargo & Company reiterated a “buy” rating on shares of Allergan PLC. in a report on Monday. Barclays PLC restated an “equal weight” rating on shares of Allergan PLC. in a research note on Monday. UBS AG restated a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Tuesday, September 26th. Credit Suisse Group restated an “outperform” rating and set a $266.00 price objective (down previously from $286.00) on shares of Allergan PLC. in a report on Tuesday, September 26th. Finally, Mizuho restated a “buy” rating and set a $267.00 price objective on shares of Allergan PLC. in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $271.84.

Shares of Allergan PLC. (AGN) opened at 209.80 on Wednesday. The company has a market cap of $70.14 billion, a price-to-earnings ratio of 6.39 and a beta of 1.15. The firm has a 50-day moving average of $220.20 and a 200 day moving average of $233.72. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the business earned $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $16.22 earnings per share for the current year.

Allergan PLC. declared that its Board of Directors has authorized a share buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.33%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/allergan-plc-agn-shares-bought-by-gluskin-sheff-assoc-inc/1607238.html.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.